Past, present, and future of Parkinson’s disease: A special essay on the 200th Anniversary of the Shaking Palsy.

J.A. Obeso, M. Stamelou, C.G. Goetz, W. Poewe, A.E. Lang, D. Weintraub, D. Burn, G.M. Halliday, E. Bezard, S. Przedborski, S. Lehericy, D.J. Brooks, J.C. Rothwell, M. Hallett, M.R. DeLong, C. Marras, C.M. Tanner, G.W. Ross, J.W. Langston, C. Klein, V. Bonifati, J. Jankovic, A.M. Lozano, G. Deuschl, H. Bergman, E. Tolosa, M. Rodriguez-Violante, S. Fahn, R.B. Postuma, D. Berg, K. Marek, D.G. Standaert, D.J. Surmeier, C.W. Olanow, J.H. Kordower, P. Calabresi, A.H.V. Schapira, A.J. Stoessl
Mov Disord.. 2017-09-01; 32(9): 1264-1310
DOI: 10.1002/mds.27115

Lire sur PubMed

1. Mov Disord. 2017 Sep;32(9):1264-1310. doi: 10.1002/mds.27115.

Past, present, and future of Parkinson’s disease: A special essay on the 200th
Anniversary of the Shaking Palsy.

Obeso JA(1)(2)(3), Stamelou M(4)(5), Goetz CG(6), Poewe W(7), Lang AE(8)(9),
Weintraub D(10)(11), Burn D(12), Halliday GM(13)(14), Bezard E(15)(16),
Przedborski S(17)(18), Lehericy S(19)(20), Brooks DJ(21)(22), Rothwell JC(23),
Hallett M(24), DeLong MR(25), Marras C(26), Tanner CM(27)(28), Ross GW(29),
Langston JW(30), Klein C(31), Bonifati V(32), Jankovic J(33), Lozano AM(34),
Deuschl G(35), Bergman H(36)(37)(38), Tolosa E(39)(40), Rodriguez-Violante
M(41)(42), Fahn S(43), Postuma RB(44), Berg D(45), Marek K(46), Standaert DG(47),
Surmeier DJ(48), Olanow CW(49), Kordower JH(50)(51), Calabresi P(52)(53),
Schapira AHV(54), Stoessl AJ(55)(56).

Author information:
(1)HM CINAC, Hospital Universitario HM Puerta del Sur, Mostoles, Madrid, Spain.
(2)Universidad CEU San Pablo, Madrid, Spain.
(3)CIBERNED, Madrid, Spain.
(4)Department of Neurology, Philipps University, Marburg, Germany.
(5)Parkinson’s Disease and Movement Disorders Department, HYGEIA Hospital and
Attikon Hospital, University of Athens, Athens, Greece.
(6)Department of Neurological Sciences, Rush University Medical Center, Chicago,
Illinois, USA.
(7)Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.
(8)Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra
Program in Parkinson’s Disease, Toronto Western Hospital, Toronto, Canada.
(9)Department of Medicine, University of Toronto, Toronto, Canada.
(10)Department of Psychiatry, Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, Pennsylvania, USA.
(11)Parkinson’s Disease and Mental Illness Research, Education and Clinical
Centers (PADRECC and MIRECC), Corporal Michael J. Crescenz Veteran’s Affairs
Medical Center, Philadelphia, Pennsylvania, USA.
(12)Medical Sciences, Newcastle University, Newcastle, UK.
(13)Brain and Mind Centre, Sydney Medical School, The University of Sydney,
Sydney, Australia.
(14)School of Medical Sciences, University of New South Wales and Neuroscience
Research Australia, Sydney, Australia.
(15)Université de Bordeaux, Institut des Maladies Neurodégénératives, Centre
National de la Recherche Scientifique Unité Mixte de Recherche 5293, Institut des
Maladies Neurodégénératives, Bordeaux, France.
(16)China Academy of Medical Sciences, Institute of Lab Animal Sciences, Beijing,
(17)Departments of Neurology, Pathology, and Cell Biology, the Center for Motor
Neuron Biology and Disease, Columbia University, New York, New York, USA.
(18)Columbia Translational Neuroscience Initiative, Columbia University, New
York, New York, USA.
(19)Institut du Cerveau et de la Moelle épinière – ICM, Centre de NeuroImagerie
de Recherche – CENIR, Sorbonne Universités, UPMC Univ Paris 06, Inserm U1127,
CNRS UMR 7225, Paris, France.
(20)Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
(21)Clinical Sciences Department, Newcastle University, Newcastle, UK.
(22)Department of Nuclear Medicine, Aarhus University, Aarhus, Denmark.
(23)Human Neurophysiology, Sobell Department, UCL Institute of Neurology, London,
(24)Human Motor Control Section, National Institute of Neurological Disorders and
Stroke, National Institutes of Health, Bethesda, Maryland, USA.
(25)Department of Neurology, Emory University School of Medicine, Atlanta,
Georgia, USA.
(26)Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra
Program in Parkinson’s disease, Toronto Western Hospital, University of Toronto,
Toronto, Canada.
(27)Movement Disorders and Neuromodulation Center, Department of Neurology,
University of California-San Francisco, San Francisco, California, USA.
(28)Parkinson’s Disease Research, Education and Clinical Center, San Francisco
Veterans Affairs Medical Center, San Francisco, California, USA.
(29)Veterans Affairs Pacific Islands Health Care System, Honolulu, Hawaii, USA.
(30)Parkinson’s Institute, Sunnyvale, California, USA.
(31)Institute of Neurogenetics, University of Luebeck, Luebeck, Germany.
(32)Department of Clinical Genetics, Erasmus University Medical Center,
Rotterdam, The Netherlands.
(33)Parkinson’s Disease Center and Movement Disorders Clinic, Department of
Neurology, Baylor College of Medicine, Houston, Texas, USA.
(34)Department of Neurosurgery, Toronto Western Hospital, University of Toronto,
Toronto, Canada.
(35)Department of Neurology, Universitätsklinikum Schleswig-Holstein, Christian
Albrechts University Kiel, Kiel, Germany.
(36)Department of Medical Neurobiology, Institute of Medical Research
Israel-Canada, Jerusalem, Israel.
(37)Edmond and Lily Safra Center for Brain Sciences, The Hebrew University,
Jerusalem, Israel.
(38)Department of Neurosurgery, Hadassah University Hospital, Jerusalem, Israel.
(39)Parkinson’s Disease and Movement Disorders Unit, Neurology Service, Institut
Clínic de Neurociències, Hospital Clínic de Barcelona, Barcelona, Spain.
(40)Department of Medicine, Universitat de Barcelona, IDIBAPS, Centro de
Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)
Barcelona, Spain.
(41)Movement Disorders Clinic, Clinical Neurodegenerative Research Unit, Mexico
City, Mexico.
(42)Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico.
(43)Department of Neurology, Columbia University Medical Center, New York, New
York, USA.
(44)Department of Neurology, McGill University, Montreal General Hospital,
Montreal, Quebec, Canada.
(45)Klinik für Neurologie, UKSH, Campus Kiel, Christian-Albrechts-Universität,
Kiel, Germany.
(46)Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA.
(47)Department of Neurology, University of Alabama at Birmingham, Birmingham,
Alabama, USA.
(48)Department of Physiology, Feinberg School of Medicine, Northwestern
University, Chicago, Illinois, USA.
(49)Departments of Neurology and Neuroscience, Mount Sinai School of Medicine,
New York, New York, USA.
(50)Research Center for Brain Repair, Rush University Medical Center, Chicago,
Illinois, USA.
(51)Neuroscience Graduate Program, Rush University Medical Center, Chicago,
Illinois, USA.
(52)Neurological Clinic, Department of Medicine, Hospital Santa Maria della
Misericordia, University of Perugia, Perugia, Italy.
(53)Laboratory of Neurophysiology, Santa Lucia Foundation, IRCCS, Rome, Italy.
(54)University Department of Clinical Neurosciences, UCL Institute of Neurology,
University College London, London, UK.
(55)Pacific Parkinson’s Research Centre, Division of Neurology & Djavadf
Mowafaghian Centre for Brain Health, University of British Columbia, British
Columbia, Canada.
(56)Vancouver Coastal Health, Vancouver, British Columbia, Canada.

This article reviews and summarizes 200 years of Parkinson’s disease. It
comprises a relevant history of Dr. James Parkinson’s himself and what he
described accurately and what he missed from today’s perspective. Parkinson’s
disease today is understood as a multietiological condition with uncertain
etiopathogenesis. Many advances have occurred regarding pathophysiology and
symptomatic treatments, but critically important issues are still pending
resolution. Among the latter, the need to modify disease progression is
undoubtedly a priority. In sum, this multiple-author article, prepared to
commemorate the bicentenary of the shaking palsy, provides a historical
state-of-the-art account of what has been achieved, the current situation, and
how to progress toward resolving Parkinson’s disease. © 2017 International
Parkinson and Movement Disorder Society.

© 2017 International Parkinson and Movement Disorder Society.

DOI: 10.1002/mds.27115
PMCID: PMC5685546 [Available on 2018-09-01]
PMID: 28887905 [Indexed for MEDLINE]

Auteurs Bordeaux Neurocampus